Dianthus Therapeutics, Inc. DNTH 深 滬
交易中 08-21 11:28:55 美东时间
111.19
+1.680
+1.53%
華盛通- 最 高112.72
- 今 開110.30
- 成交量 26.75万股
- 最 低 108.9521
- 昨 收 109.51
- 總市值 62.19亿
- 52周最高 117.875
- 市盈率 靜 --
- 換手率 0.48%
- 52周最低 23.39
- 委 比 -4.76%
- 總股本 5593.44万
- 歷史最高 336.00
- 量 比 1.46
- 振 幅 3.44%
- 歷史最低 5.136
- 每 手 1
- 風險率 27.15%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多美股大行评级 | AMD、Arista Networks、Booking 、加特纳、Pinterest、科力斯、Wayfair等获多家大行上调目标价
今日重点评级关注：HC Wainwright & Co.：维持Precigen"买入"评级，目标价从14美元升至18美元；HC Wainwright & Co.：维持Sophia Genetics"买入"评级，目标价从12美元升至14美元
08-06 11:36
美股大行评级 | 潜在涨幅3586.64%！HC Wainwright上调Enlivex目标价至80美元，维持"买入"评级
今日重点评级关注：HC Wainwright & Co.：维持Enlivex"买入"评级，目标价从20美元升至80美元；Canaccord Genuity：维持Pharming Group NV Sponsored ADR"买入"评级，目标价从37美元升至38美元
08-04 11:45
Evercore ISI Group Maintains Outperform on Dianthus Therapeutics, Raises Price Target to $134
Evercore ISI Group analyst Gavin Clark-Gartner maintains Dianthus Therapeutics (NASDAQ:DNTH) with a Outperform and raises the price target from $120 to $134.
08-03 23:03
Why Is Dianthus Therapeutics Stock Trading Higher On Friday?
Dianthus Therapeutics Inc. (NASDAQ:DNTH) reported stronger-than-expected midstage results from its CAPTIVATE Phase 3 trial of claseprubart (DNTH103) in chronic inflammatory demyelinating polyneuropathy (CIDP). An interim analysis of 40 patients completing Part A showed a 75% confirmed responder rate...
06-13 01:20
Sanofi Trial Setback May Reinforce Argenx Vyvgart's Position: Analyst
Sanofi SA (NASDAQ:SNY) on Wednesday announced that it will discontinue its Phase 3 MOBILIZE study evaluating riliprubart in patients with chronic inflammatory demyelinating polyneuropathy (CIDP) who had not responded to standard treatments. CIDP is a rare, acquired autoimmune disorder of the periphe...
06-11 21:09
今日药闻 | BI、GSK、拜耳、礼来等新进展……
1.5月6日，瑞博生物宣布与勃林格殷格翰（BI）在代谢功能障碍相关脂肪性肝炎（MASH）领域的siRNA合作达成第三个关键里程碑 此次进展标志着双方合作研发进...
05-07 17:24
美股大行评级 | 潜在涨幅20%！15家机构集体上调AMD目标价；Lumentum、神经分泌生物科学、伊顿公司、美国电力等获多家大行上调目标价
今日重点评级关注：Citizens：维持Avalo Therapeutics"跑赢大市"评级，目标价从52美元升至62美元；BTIG：维持Avalo Therapeutics"买入"评级，目标价从40美元升至58美元
05-07 12:37
Wedbush Maintains Outperform on Dianthus Therapeutics, Raises Price Target to $105
Wedbush analyst Laura Chico maintains Dianthus Therapeutics (NASDAQ:DNTH) with a Outperform and raises the price target from $103 to $105.
05-06 20:45
Dianthus Therapeutics Q1 EPS $(0.85) Beats $(1.07) Estimate, Sales $463.000K Beat $354.214K Estimate
Dianthus Therapeutics (NASDAQ:DNTH) reported quarterly losses of $(0.85) per share which beat the analyst consensus estimate of $(1.07) by 20.56 percent. This is a 3.66 percent decrease over losses of $(0.82) per share
05-06 04:29
美股大行评级 | 小摩上调Lumentum控股目标价从565美元升至950美元；大小摩齐上调美国铝业目标价
今日重点评级关注：Ascendiant Capital：维持RenovoRx"买入"评级，目标价从13美元升至13.5美元；Ascendiant Capital：维持Lucid Diagnostics"买入"评级，目标价从8.25美元升至9美元
04-10 18:27
